Form 4: Leap Therapeutics Director Acquires Stock Options

Christopher Mirabelli, a director at Leap Therapeutics, acquired stock options for 85,000 shares on October 2, 2024.

Summary

• Christopher Mirabelli, a director of Leap Therapeutics, Inc. (LPTX), reported a transaction on October 2, 2024.
• Mirabelli acquired stock options for 85,000 shares of common stock at an exercise price of $2.45 per share.
• The options were granted under Leap's 2022 Equity Incentive Plan and vest in 36 equal monthly installments, starting one month after the grant date, contingent upon continued service to the company.
• Following the transaction, Mirabelli directly owns options for 85,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction involving stock options, which is a routine occurrence. The director's acquisition of options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options (36 equal monthly installments) suggests a long-term commitment from the director to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Key Dates